Contact:
PRISM BioLab Co., Ltd.
info@prismbiolab.com

26-1, Muraoka-Higashi 2chome. Fujisawa,Kanagawa 251-8555
www.prismbiolab.com

PRESS RELEASEPRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on aProtein-Protein Interaction Target•Collaboration focused on discovering oral inhibitors of protein-protein interaction (PPI)targets by leveraging PRISM BioLab’s proprietary PepMetics® technology.

•PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus
royalties on net sales.
TOKYO, Japan, 28 Nov 2023: -- PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development
biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets,today announced that it has entered into a License and Collaboration Agreement with Eli Lilly andCompany (“Lilly”).
Under the agreement, PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target
selected by Lilly utilizing PRISM’s proprietary PepMetics® technology. Lilly has the option to add up to two
more targets to the collaboration and is responsible for the clinical development and commercialization ofresulting products. PRISM will receive upfront payments and is eligible to receive up to $660 million in preclinical, clinical and commercial development milestones payments, as well as royalties on product sales.
“We are very excited to enter into this collaboration with Lilly as we apply our technology to expand thefield of drug discovery into a novel approach to drug the PPI targets,” said Dai Takehara, President andChief Executive Officer of PRISM Biolab. “Our PepMetics® technology holds promise to change the current
paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with smallmolecules. This collaboration with Lilly, an innovative global pharma company, could help us realize thisvision and expand the field of druggable targets for the benefit of patients.”
About PRISM BioLabPRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics®
technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targetsand transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics®
are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn,the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By
combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics®
technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand thefield of drug discovery by turning previously undruggable PPIs into targets readily druggable with smallmolecules and by generating oral small molecule alternatives for injectable biologics.
PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies.
PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals are inclinical development for cancer and liver disease, respectively.
www.prismbiolab.com